TRISHULA THERAPEUTICS

Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class anti-CD39 antibody... Our focus is on developing transformational cancer medicines by targeting the mechanisms of immune evasion in the tumor microenvironment. TTX-030, a novel, first-in-class antibody, has been studied in two Phase 1/1b clinical studies in multiple solid tumors and now undergoing a randomized Phase 2 study in frontline metastatic pancreatic cancer.

Also known as: Trishula Therapeutics, Inc.

Primary location: South San Francisco United States